477 related articles for article (PubMed ID: 33012318)
21. Monoclonal antibody therapy in sinonasal disease.
Chiarella SE; Sy H; Peters AT
Am J Rhinol Allergy; 2017 Mar; 31(2):93-95. PubMed ID: 28281440
[TBL] [Abstract][Full Text] [Related]
22. Real-Life Experience of Monoclonal Antibody Treatments in Chronic Rhinosinusitis with Nasal Polyposis.
Meier EC; Schmid-Grendelmeier P; Steiner UC; Soyka MB
Int Arch Allergy Immunol; 2021; 182(8):736-743. PubMed ID: 33756474
[TBL] [Abstract][Full Text] [Related]
23. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
Chen S; Zhou A; Emmanuel B; Thomas K; Guiang H
Curr Med Res Opin; 2020 Nov; 36(11):1897-1911. PubMed ID: 32847417
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Vidian Neurectomy on Pulmonary Function in Patients with Allergic Rhinitis and Chronic Rhinosinusitis with Nasal Polyps.
Maimaitiaili G; Kahaer K; Tang L; Zhang J
Am J Med Sci; 2020 Aug; 360(2):137-145. PubMed ID: 32423746
[TBL] [Abstract][Full Text] [Related]
25. Clinical and biological markers in disease and biologics to treat chronic rhinosinusitis.
Guo CL; Wang CS; Liu Z
Curr Opin Allergy Clin Immunol; 2022 Feb; 22(1):16-23. PubMed ID: 34789677
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
27. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis.
Shin HW; Kim DK; Park MH; Eun KM; Lee M; So D; Kong IG; Mo JH; Yang MS; Jin HR; Park JW; Kim DW
J Allergy Clin Immunol; 2015 Jun; 135(6):1476-85.e7. PubMed ID: 25725991
[TBL] [Abstract][Full Text] [Related]
28. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis.
Bachert C; Zhang L; Gevaert P
J Allergy Clin Immunol; 2015 Dec; 136(6):1431-1440. PubMed ID: 26654192
[TBL] [Abstract][Full Text] [Related]
29. Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
Kartush AG; Schumacher JK; Shah R; Patadia MO
Am J Rhinol Allergy; 2019 Mar; 33(2):203-211. PubMed ID: 30587005
[TBL] [Abstract][Full Text] [Related]
30. Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy.
Kariyawasam HH; James LK
Drug Des Devel Ther; 2020; 14():5483-5494. PubMed ID: 33328726
[TBL] [Abstract][Full Text] [Related]
31. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.
Humbert M; Bousquet J; Bachert C; Palomares O; Pfister P; Kottakis I; Jaumont X; Thomsen SF; Papadopoulos NG
J Allergy Clin Immunol Pract; 2019; 7(5):1418-1429. PubMed ID: 30928481
[TBL] [Abstract][Full Text] [Related]
32. Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review.
Kim C; Han J; Wu T; Bachert C; Fokkens W; Hellings P; Hopkins C; Lee S; Mullol J; Lee JT
Otolaryngol Head Neck Surg; 2021 Jan; 164(1):57-66. PubMed ID: 32746710
[TBL] [Abstract][Full Text] [Related]
33. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
Lelegren MJ; Son SY; Han JK; Lam KK
Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis.
Mostafa BE; Fadel M; Mohammed MA; Hamdi TAH; Askoura AM
Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):121-128. PubMed ID: 31552526
[TBL] [Abstract][Full Text] [Related]
35. Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.
Olivieri B; Tinazzi E; Caminati M; Lunardi C
Immunol Allergy Clin North Am; 2020 Nov; 40(4):649-665. PubMed ID: 33012326
[TBL] [Abstract][Full Text] [Related]
36. Biologics for Atopic Dermatitis.
Boguniewicz M
Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
[TBL] [Abstract][Full Text] [Related]
37. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
Bajpai S; Marino MJ; Rank MA; Donaldson AM; O'Brien EK; Lal D
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1152-1161. PubMed ID: 33527730
[TBL] [Abstract][Full Text] [Related]
38. The role of biologics in chronic rhinosinusitis: a systematic review.
Iqbal IZ; Kao SS; Ooi EH
Int Forum Allergy Rhinol; 2020 Feb; 10(2):165-174. PubMed ID: 31869863
[TBL] [Abstract][Full Text] [Related]
39. Is generative pre-trained transformer artificial intelligence (Chat-GPT) a reliable tool for guidelines synthesis? A preliminary evaluation for biologic CRSwNP therapy.
Maniaci A; Saibene AM; Calvo-Henriquez C; Vaira L; Radulesco T; Michel J; Chiesa-Estomba C; Sowerby L; Lobo Duro D; Mayo-Yanez M; Maza-Solano J; Lechien JR; La Mantia I; Cocuzza S
Eur Arch Otorhinolaryngol; 2024 Apr; 281(4):2167-2173. PubMed ID: 38329526
[TBL] [Abstract][Full Text] [Related]
40. Current and Future Treatments of Rhinitis and Sinusitis.
Patel GB; Kern RC; Bernstein JA; Hae-Sim P; Peters AT
J Allergy Clin Immunol Pract; 2020 May; 8(5):1522-1531. PubMed ID: 32004747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
